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The need for a network to establish
and validate predictive biomarkers in cancer
immunotherapy
Giuseppe V. Masucci1* , Alessandra Cesano2, Alexander Eggermont3, Bernard A. Fox4, Ena Wang5,
Francesco M. Marincola6, Gennaro Ciliberto7, Kevin Dobbin8, Igor Puzanov9, Janis Taube10, Jennifer Wargo11,
Lisa H. Butterfield12, Lisa Villabona1, Magdalena Thurin13, Michael A. Postow14,15,16, Paul M. Sondel17,
Sandra Demaria18, Sanjiv Agarwala19 and Paolo A. Ascierto20*

Abstract
Immunotherapies have emerged as one of the most promising approaches to treat patients with cancer. Recently, the
entire medical oncology field has been revolutionized by the introduction of immune checkpoints inhibitors. Despite
success in a variety of malignancies, responses typically only occur in a small percentage of patients for any given
histology or treatment regimen. There are also concerns that immunotherapies are associated with immune-related
toxicity as well as high costs. As such, identifying biomarkers to determine which patients are likely to derive clinical
benefit from which immunotherapy and/or be susceptible to adverse side effects is a compelling clinical and social
need. In addition, with several new immunotherapy agents in different phases of development, and approved therapeutics being tested in combination with a variety of different standard of care treatments, there is a requirement to
stratify patients and select the most appropriate population in which to assess clinical efficacy. The opportunity to
design parallel biomarkers studies that are integrated within key randomized clinical trials could be the ideal solution. Sample collection (fresh and/or archival tissue, PBMC, serum, plasma, stool, etc.) at specific points of treatment
is important for evaluating possible biomarkers and studying the mechanisms of responsiveness, resistance, toxicity
and relapse. This white paper proposes the creation of a network to facilitate the sharing and coordinating of samples
from clinical trials to enable more in-depth analyses of correlative biomarkers than is currently possible and to assess
the feasibilities, logistics, and collated interests. We propose a high standard of sample collection and storage as well
as exchange of samples and knowledge through collaboration, and envisage how this could move forward using
banked samples from completed studies together with prospective planning for ongoing and future clinical trials.
Introduction
Concept 1. The need for biomarker discovery
and validation in cancer immunotherapy

Immunotherapies have emerged as one of the most
promising approaches to treat patients with cancer.
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Recently, the entire medical oncology field has been revolutionized by the introduction of immune checkpoint
inhibitors, including T cell inhibitory receptors such as
cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4)
and programmed cell death-1 (PD-1) or its ligand (PDL1). However, despite well documented success in a variety of malignancies, responses typically only occur in a
small percentage of patients for any given histology or
treatment regimen. There are also concerns associated
with immune-related toxicity and the high cost of immunotherapies. Because of this, identifying biomarkers to
determine those patients that are most likely to derive
clinical benefit from different immunotherapies and
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those who are more prone to develop adverse side effects
is a compelling clinical and social need. Moreover, with
several new immunotherapy agents in different phases
of development, and approved therapies being evaluated
in various combinations with different standard of care
treatments, there is an urgent requirement to stratify
patients and select the most appropriate populations in
which to assess clinical efficacy.
Because of the complexity of the immune response,
tumor heterogeneity and patient diversity, it is unlikely
that a single biomarker will be sufficient to predict clinical outcomes in response to the spectrum of immunetargeted therapies. Biomarkers which are correlated with
clinical outcome can be identified at molecular (genetics,
epigenetics, metagenomics, proteomic, metabolomics,
etc.), cellular and tissue levels. Before a candidate biomarker and/or new technology can be used for treatment
decisions in a clinical setting, several steps are necessary
to demonstrate its clinical validity. The discovery and
assessment of biomarkers using cutting edge technologies across different clinical studies is a fundamental step
in maximizing data generation. Collaborative efforts to
combine clinical trial samples and data will empower
data analysis and the significance of any biomarkers
identified.
A biomarker with clinical relevance requires rigorous validation which can be separated into several
sequential steps: assessment of basic assay performance (analytical validation); characterization of the
assay performance with regard to its intended use
(clinical validation); validation in clinical trials that
ensures that the assay performs robustly according
to predefined specifications (fit-for-purpose) and the
establishment of definitive acceptance criteria for
clinical use (validation of clinical utility). The fit-for
purpose approach (an umbrella term used to describe
distinct stages of the validation process) for biomarker
development and validation addresses the proper
assay tailored to meet the intended purpose of the
biomarker. The Society for Immunotherapy of Cancer (SITC) Immune Biomarkers Task Force convened
to address this need in this two-volume series; preanalytical and analytical (Volume I) as well as clinical
and regulatory (Volume II) aspects of the validation
process as applied to predictive biomarkers for cancer
immunotherapy [1, 2].
Clinical study design in which biomarker analysis is
one of the primary objectives/endpoints needs to be promoted. A good example of such a study was CA184-004
(NCT00261365), a phase II trial to determine predictive
markers of response to ipilimumab (MDX-010). In this
study, the primary endpoint was to identify candidate
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markers predictive of response and/or serious toxicity
to ipilimumab. Tissue and blood samples were collected
at different time points from enrolled patients and the
subsequent biomarker analyses generated interesting
data. The findings of this study could have been considered as the first evidence for biomarker association with
outcome, and could potentially have been confirmed and
prospectively validated in subsequent studies. However,
study results can often not sufficiently meet expectations
or may be contradictory, which may be in part due to the
constraints of underpowered cohort size, variables in
the time and type of sample collection, and differences
in procedures, data generation and tools used at different sites. The opportunity to design parallel biomarker
studies that are integrated as key components of important randomized clinical trials could offer a solution.
Sample collection (fresh and/or archival tissue, PBMC,
serum, plasma, stool, etc.) at specific stages of treatment
is important to evaluate possible biomarkers and to
study mechanisms of response, resistance, toxicity and
relapse. Such studies would be helpful in the design and
development of upcoming therapies. At present, several
research institutes around the world, including many at
which the authors of this article are based, are collecting tumor, blood, serum and faecal samples to investigate prognostic and predictive biomarkers and to better
understand the complex immunobiology of patients and
their cancers.
Biomarker discovery is a fundamental objective in
the design of many clinical trials. Therefore, the incorporation of correlative biomarker studies using stateof-the-art technologies within clinical trials in order to
maximize data generation is required. The challenge at
this stage is that most completed or ongoing clinical trials
have not sufficiently incorporated biomarker assessment
into their design. There is a need for an international
joint effort to maximize data, information and knowledge
generation from existing and completed clinical trials
and to design clinical trials that will better address these
important issues.
The proposal of this white paper is to encourage the
creation of a network to facilitate the sharing and coordinating of samples from clinical trials in order to allow
more in-depth analyses of correlative biomarkers than is
currently possible. The feasibility, logistics, and various
stakeholder interests in such a network are also considered. A high standard of sample collection and storage as
well as the exchange of samples and knowledge through
collaboration is proposed, and we envisage how this
could move forward with banked samples from completed studies as well as with the prospective planning of
ongoing and future clinical trials.

Masucci et al. J Transl Med (2017) 15:223

Concept 2. The proposal of an international cancer
immunotherapy biomarker consortium

There are a number of compelling arguments for the
establishment of an international cancer immunotherapy biomarker consortium, which are summarized
below.
1. To maximize the potential of novel biomarker discovery using samples from multi-institutional clinical practice and clinical studies and will offer a new
breadth of experience and expertise to biomarker
studies.
2. To allow streamlined sample access by developing
online registration, biobanking, and the inventory
and tracking of archived samples in order to best
utilize samples existing after designated trials completed.
3. To set up and share standard operating procedures
(SOPs) to harmonize future sample collection processing and banking.
4. To improve access to samples by initiating a new
patient sample registry or by joining forces with
existing international clinical trial patient registries
with available clinical data and biological sample
collection, including storage conditions and inventory information.
5. To provide support/guidelines in correlative study
design.
6. To engage and leverage with cancer societies,
pharma and biotech companies, and government
institutes in order to improve the development of
biomarkers.
7. To accelerate biomarker development by bringing
together groups from around the world that can collaborate from proof-of-concept to validation. Moreover, the experience of the immunoscore worldwide
project, coordinated by SITC, is an important example of an ‘honest broker’ approach for coordinating
a specific study and data sharing [3].
8. To reinforce the concept of a stable-standing consortium which would be able to take a short, intermediate and long-term view towards biomarker
development for more effective care of patients with
cancer.
In order to emphasize the point 4# proposal above and
to have data on as large a group of patients as possible, it
would be very beneficial to have a stable-standing consortium among the major contributing institutions, societies
and research centers. Recently, a consortium organized
by The University of Tubingen was able to collect samples from several different institutions and obtain results
from a large number of patients treated with Ipilimumab
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or an anti-PD-1 (Nivolumab or Pembrolizumab) [4]. The
worldwide Immunoscore project is another good example of a effective consortium that was successful at validating a previously described biomarker [3].
Concept 3. The challenges in biomarker discovery

A series of challenges are confronted when a project of
this magnitude is proposed:
1. Limited or fragmented resources.
2. Insufficient numbers of patients per cohort.
3. Inclusion of patients with diverse treatment history
(previous antitumoral treatment), histological and
radiographic conditions.
4. Limited and/or suboptimal correlative study design
due to funding and/or regulatory constraints.
5. Heterogeneity in the types of biological samples with
different time points of collection, storage conditions, platforms used for data generation, lab-driven
SOPs and data analysis algorithms and tools.
6. Heterogeneity in the clinical data collected and the
length of follow-up,
7. Lack of international joint initiatives.
8. Potential intellectual property.
Previous programs that utilized treatment stratification biomarkers had higher success rates at each phase of
development versus the overall dataset [5]. Moreover, the
importance of determining biomarkers for both patient
selection for treatment and selection of treatment for the
patient is of utmost importance. As an example, assessment of tumor PD-L1 status is not critical for selecting
patients with metastatic melanoma for treatment with
anti-PD-1 inhibitors (Pembrolizumab or Nivolumab). In
fact, patients with PD-L1 negative tumors may receive
long-term benefit from anti-PD-1/PD-L1 treatment.
However, PD-L1 status might be important for selecting
patients for combination treatment (e.g. anti-CTLA-4
and anti-PD-1). Currently available data show that overall survival (OS) in PD-L1 positive patients treated with
combined anti-CTLA-4 and anti-PD-1 is not superior
to nivolumab monotherapy. This finding raises the question of why should these patients be treated with a more
toxic regimen if the same benefit is achieved with less
toxic monotherapy? However, PD-L1 expression is not
the best example of a biomarker for patient selection in
the context of checkpoint inhibitors. Although patients
with strongly positive (> 50% on tumor cells) PD-L1
tumors clearly had an advantage for anti-PD-1 therapy
versus chemotherapy in the Keynote 024 study, it is less
clear why the same patient population did not show the
same advantage from nivolumab therapy in the CheckMate 026 pivotal study [6]. Anti-PD-1/PD-L1 treatments
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showed similar efficacy across different clinical trials and
the problem may be in the IHC assay and the ‘immunological’ characterization/criteria used to evaluate PD-L1
positivity. However, the FDA recently (11th May 2017)
approved the combination of chemotherapy with pembrolizumab for first-line treatment of NSCLC regardless
of PD-L1 expression, confirming the need for predictive
biomarkers [7].
Over 10 years ago, the FDA issued important guidance that all drugs should be accompanied by a companion diagnostic (CDx). Industry has applied a
thorough understanding of biology and the immune
system to develop robust and meaningful biomarkers.
While industry may believe that leveraging biomarkers and companion diagnostics are critical to precision
medicine, developing them is challenging and expensive and therefore has been less of a priority. On the
other hand, the introduction of Pembrolizumab in
clinical trials should be an example to others. Industry efforts might be helped by strategic partnerships
with academic institutions in order to identify relevant clinical biomarkers. For example, the processes
of detecting reproducible, predictive biomarkers and
developing robust companion diagnostics substantially benefit from the correlation to genomics and
complex tissue analysis data. This includes the analysis of spatial relationships between immune cells hosting the tumour environment and the development of
highly sensitive, precise, quantifiable and reproducible
assays. These issues are challenging, time-consuming
and need large investment. Pursuing a thorough, evidence-based and scientifically-driven drug discovery
and development program is the desired long-term
goal. However, funds to support these programs could
be used for more short-term plans such as recruiting
additional patient groups into a clinical trial in order
to meet regulatory objectives.
At present, the best example of a truly successful and
important immune-oncology predictive biomarker
is mismatch repair deficiency: Cancer patients with
microsatellite instability high (MSI-H) tumors independent of the tissue of origin benefit from immunotherapy with PD-1 inhibitors [8]. In particular, in
colorectal cancer, MSI-H patients experience up to 50%
or higher responses, while few if any responses are seen
in MSI-low (L) colorectal cancer patients. Clinical demonstration of this concept has led to a recent approval
by the FDA. We believe that these two examples of single predictive biomarkers (i.e. PD-L1 and MSI) will be
the exception and not the rule and that we will have to
search for the integration of several different biomarkers. This will amplify the challenge and will require a
highly coordinated effort across multiple institutions.
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Patient inclusion and statistical considerations according
to the study design

The development and implementation of appropriate
biomarker assays to study T cells and other cells in the
microenvironment is an essential companion objective
for clinical trials that seek to evaluate immunotherapeutic agents, particularly when used in combination.
In principle, the efficacy of a compound (in this case
immune-targeted agents) is at least partially dependent
on the presence of the target in the tumor. In an ideal
scenario, when complete information on predictive factors and proper selection of patients can be obtained in
the early phases of drug development (phase I–II studies), the conduct of subsequent phase III studies could
be optimized. Unfortunately, this ideal scenario rarely
occurs. The clinical immune-oncology research community is dealing with several key questions, including; (a)
what metrics are best for biomarker evaluation in phase
III studies, (b) what primary and secondary endpoints
should ne assessed, and (c) what are the statistical properties of various metrics. When planning a phase III trial
comparing an experimental treatment with the standard,
we often have evidence supporting a predictive role of
a biomarker, whereas patients with the absence of such
expression should not respond. In such a scenario, different strategies are theoretically possible (see Fig. 1):
(i) a ‘randomize all’ strategy, i.e. randomization between
standard and experimental treatment without selection,
possibly with stratification based on biomarker status
(in this case, ‘stratified trial design’ or ‘treatment-marker
interaction design’); (ii) ‘targeted’ design, i.e. randomization between standard and experimental treatment only
in patients selected according to the status of the marker
(also called ‘enrichment design’); and (iii) ‘customized’
strategy (also called ‘marker-based strategy’), i.e. randomization between a standard arm in which the treatment is the same for all patients, and a personalized arm
in which treatment is chosen on the basis of the marker
status of each patient.
How can we develop a predictive biomarker in a more
efficient way? The experience of the worldwide consortium on Immunoscore could be leading the way in
finding different trial methods for evaluating immuneoncology biomarkers. We could also consider an opposite
approach to the classical flow suggested in Fig. 1 in which
biomarkers are validated first. The challenge in this case
is in the ability of statistics to find the correct solutions
and avoid decades-long clinical trials. Since biomarkers have been validated preclinically they could be used
in different cohort studies for clinical predictive analysis. This could immediately eliminate the lack of effective information in those markers that do not reach the
desired endpoint.

Masucci et al. J Transl Med (2017) 15:223

Page 5 of 10

Fig. 1 Procedures for discovery and validation of biomarkers. Alternative designs of randomized phase III trials in the presence of a potentially predictive marker of efficacy of treatment. BM + , positive biomarker; BM − , biomarker negative. Bottom left, “randomize-all” design with determination and prospective stratification of BM + and BM − patients. Center, “targeted” design. Right, “customized” design
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Methods
To address these challenges, a systematic approach
involving a multi-institutional effort could help identify
and develop robust, standardized biomarkers and related
clinical data that support the selection and testing of
promising therapeutic approaches and combinations. The
diversity of reagents and platforms that are being used to
assess the immune systems of humans and data reporting procedures are not consistent. This hampers data
reproducibility among laboratories, which may prevent
meaningful interpretations across studies and could lead
to selection of different intent-to-treat (ITT) populations.
Most of the assays being used involve high-throughput
multi-parametric ‘signatures’ that require considerable
statistical and bioinformatic efforts for proper algorithm
development and robust data interpretation. The requisite capabilities are not available to all investigators assaying immune biomarkers and are not consistently being
accomplished in academic or clinical laboratories due
to resource constraints. This issue must be addressed to
ensure that biomarker measurements using high-quality,
validated assays can be compared between clinical trials.
The use of different assays, if there are standards or reference materials available, could allow for evaluation and
comparison of performance across the assays and across
different sites. There is no current system that can easily
integrate analyses across different clinical trials.
Different approaches to overcome these limitations and
to address different technical and logistical challenges
have evolved in the process of biomarker standardization.
a. A central laboratory approach is able to provide
integrated testing, sample management, and datamanagement services; therefore, it may be able to
supply efficient and reliable biomarker testing and
data delivery as part of comprehensive biomarker
characterization. A small, integrated network of laboratories with specific expertise in an array of molecular and cellular approaches, testing blood and tumor
samples, would be able to support coordinated and
standardized biomarker investigation, sample sharing
and data sharing.
b. An alternative approach that facilitates the comparability and integration of data across multiple laboratories is assay harmonization (proficiency paneldriven SOPs, approaches and troubleshooting).
Harmonization of biomarker assays enforces identical reagents and/or protocols across laboratories
and the establishment of assay-specific protocols in
individual laboratories. The harmonization process
involves the participation of multiple laboratories in
a consortium-based iterative testing process to identify the variables crucial for assay performance, with
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data sharing and sometimes centralized analysis. The
‘Immunoscore’ validation initiative is an example of
this approach.
c. An example that addresses comparability of
approach across multiple IHC-based PD-L1 tests was
addressed by the Blueprint Project developed by four
pharmaceutical companies (Bristol-Myers Squibb,
Merck & Co. Inc., AstraZeneca PLC, and Genentech,
Inc.) [9].

The network
Samples associated with clinical outcomes from clinical
practice or clinical studies are an enormous resource for
the identification of biomarkers that is often underutilized. We propose developing an International Immunotherapy Biomarkers Consortium to overcome barriers to
the use of these samples and associated clinical information and to optimize the information that can be learned
from them. This can help the development of biomarkers from proof-of-concept to validation. Moreover,
the experience of the Immunoscore worldwide project
coordinated by SITC is an important example of how to
work in this field. The network should be a permanent
consortium with a virtual biobank that can be accessed
as soon as an investigator from the Consortium has a scientifically valid idea. Suggestions for such a consortium
include:
1. A survey to establish the need and willingness of different institutions to participate with time, reagents,
and sample sets. This would involve development of
a subcommittee to explore issues and strategies for
sharing licensing and royalty income for IPs developed from the consortium with centers who participate in providing tissue samples and scientific expertise.
2. A database and registry of ongoing international clinical trials; clinical information including outcome;
survey of sample type and availability; clinical and
experimental data have already been completed [4].
This exercise will help identify gaps, unify standards
and understand the willingness of participants.
3. A committee to propose overall direction and identify projects to pursue, based on data-based information and sample availability. Other responsibilities of
this committee would include:
a.
b.
c.

Announcing survey results and providing database access to all participants.
Requesting proposals from participants and the
broader community.
Seeking sponsorship from venture capital,
pharma, society, and private funding (with the
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d.

possibility to have exclusive rights to develop
companion diagnostics).
Review proposals and grant-selected projects
with sample access for phase I discovery up to
phase III validation studies. The consortium
will develop policies and procedures to ensure
that samples will be used in the most effective,
ethical way and to maximize data generation
and knowledge generation using state-of-the-art
methodology germline and somatic genetic analysis (SNP, NGS, CNV, TCR).

i.

Epigenetics (transcription, methylation, miRNA,
splicing variation, fusion transcripts, transcription
regulation).
ii. Proteomics (serum/plasma protein profiling, cytokine
assays, antibody screen, exosome analysis,
iii. Metabolomic profiling.
iv. Microbiome/virome analysis.
v. Flow cytometry, Single cell network analysis, sorted
cells, functional and phenotypic profiling.
vi. Evaluation of the tumor and relationship of immune
cells with image analysis and machine learning (Multiplex IHC, Immunoscore, CyTOF).
vii. Pharmacogenomics.
viii. ImmunoPET.
e.
Monitor project progression and outcome.
f.
Present updates to the consortium at international meetings.
g. Publish results of discovery as a consortium
in an open access journal and make databases
available in format similar to TCGA.
h. Coordinate biomarker validation.

Objectives
Objectives of this consortium are outlined below.
••  The creation of a database of available samples, with
linked key information would be a top priority. This
effort could start with the trial titles/therapeutics
tested and basic trial design, number of patients,
timepoints and the nature of biospecimens obtained,
for a first review.
••  Every participant would keep the samples on site but
provide the information on this centralized database. An
app that facilitates the collection of the data preserving
the deidentified nature of the information is essential.
This could also be designed to allow a relevant search
engine to find samples based on specific characteristics.
••  A committee would evaluate proposals after samples
have been identified that may be suitable for a specific project.
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••  A network of bioinformaticians would be established
with the purpose of developing new algorithms capable to interpret and integrate data coming from the
analysis of different parameters/biomarkers (Fig. 2).
••  A task force should be created with the intent to
facilitate the discovery and development of predictive
biomarkers.

Discussion
The main goal of this white paper is to develop the framework for a network of institutes with widespread sharing
of available samples and clinical data. This will facilitate
the exchange of knowledge and collaboration in suggesting upcoming clinical trials.
There are ongoing projects that could be partners such
as the Foundation for the NIH Biomarker Consortium,
in which projects are discussed among biomarker specialists, but then funded through collaborative industry
funding in a ‘pre-competitive space’ where companion
diagnostics are not yet ready to be developed by individual companies. In addition, the four existing working
groups of the SITC Immunotherapy Biomarkers Task
Force (http://sitc.sitcancer.org/about-sitc/initiatives) currently consist of a broad array of expertise in standardization and validation of biomarkers, new technologies,
systematic high throughput approaches and baseline and
tumor-focused biomarkers. In concert with these centralized steering committees, the involved academic centers
that have clinical trials and individual biomarker expertise, would discuss what they have banked and what projects could be performed together.
Although it is relatively straightforward to create an
Internal Cancer Immunotherapy Consortium, the major
challenge is to execute the plan or methods of the network as described here. This requires stepwise planning
and strategies based upon ‘what you have’ to ‘how you
do’ to ‘what you could offer’ to ‘all we could achieve’. Both
the central laboratory approach and alternative approach
could start with retrospective biomarker analyses based
upon samples which have been collected from immunotherapy trials from sites participating in the consortium,
in order to highlight the quality of biomarker work from
this consortium. The consortium could then work with
pharmaceutical companies to launch potential prospective clinical trials to validate biomarkers. In addition,
following the achievements of PD-L1 companion diagnostics for cancer immunotherapy, the consortium could
initiate and facilitate efforts on transferring validated
biomarkers such as RNA expression profile, tumor mutational burden to companion diagnostics. A clear, feasible and effective strategy will ensure the success of this
consortium.
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Fig. 2 Reconstruction from Fig. 1

The concept of a network of collaborating biomarker
discovery/validation efforts raises the critical question
of potential mechanisms for financing this effort. Several
initiatives are already emerging in this arena. In spring
2017 in the USA, the NCI initiated an effort that is supported with funds from the Beau Biden Cancer Moonshot Initiative (through peer review and NCI-support)
for four separate laboratory centers to function as Clinical Immunotherapy Monitoring and Assessment Centers
(CIMACs). However, the CIMAC laboratories network
will serve NCI clinical trials in immunotherapy and
would not have the capacity to integrate with other clinical trial networks/consortia. Perhaps in the future with

more funding and expanded infrastructure this would be
possible. These laboratory networks will engage in separate yet integrated laboratory activities using established
and innovative platforms to evaluate both biomarkers
and other surrogate endpoints for ongoing and future
NCI sponsored cancer immunotherapy studies. This
network could serve as an important model for correlative study infrastructure in other clinical trial networks
and expanded interactions and coordination with other
immune-oncology clinical laboratories for assessment
and monitoring of biomarkers, at a global level.
The suggested international consortium for establishing and validating predictive biomarkers could
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participate in correlative biomarker science in clinical
trials and also post-trial analyses in a systematic manner.
This consortium could be very closely connected with
clinical trials in immunotherapy including existing networks (e.g. the NCI supported Cancer Immunotherapy
Trial Network, CITN) and all other ongoing trials in the
US and Europe. Most trials will likely be small cohort
studies. The consortium could combine several types of
trials and analyze them across studies in an interdisciplinary approach. It is important to keep in mind possible
bottlenecks. For instance, the US National Clinical Trials Network (NCTN, formerly the cooperative groups)
has been attempting to develop a shared database across
multiple specimen banks for some time and has found it
to be a very complex task. Different institutes track different sample parameters and sharing any patient identifiers will be a concern with regard to privacy regulations.
This is an issue that might be solved by applying similar
parameters to categorize samples collected at each institution. Another example is the database for the pediatric brain cancer consortium, run at CHOP (Children’s
Hospital of Philadelphia) using RedCap software with
restricted consortium-only access [10]. While this is feasible, it requires expertise and personnel with dedicated
effort.
In order to maintain solid communication and upto-date information flow, the consortium could have
monthly discussions and generate white papers summarizing promising data and outlining validation that could
become high priority research initiatives to be taken on
by the consortium or by other larger clinical trial groups
with the capacity for such larger studies.
There are many important details that will require
resolution in order to initiate a functional consortium
able to pursue even a fraction of the objectives identified
as important in this report. Moving forward will benefit from face-to-face discussions among a committed
group of stakeholders, consisting of immune-oncology
researchers with expertise in preclinical testing, clinical trials, and state-of-the-art laboratory evaluations
of preclinical and clinical immunotherapy regimens.
Convening a full-day workshop of such stakeholders,
potentially at a SITC meeting, or a separate meeting of
worldwide leaders in immune-oncology, may provide
the time, focus, discussions, and interactions needed to
help convert some of the helpful goals and concepts presented here into a prioritized action plan that might help
promote this vision and enable additional next steps to
proceed.
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